These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33765432)

  • 21. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer's Disease.
    Petersen KK; Ezzati A; Lipton RB; Gordon BA; Hassenstab J; Morris JC; Grober E
    J Prev Alzheimers Dis; 2023; 10(1):112-119. PubMed ID: 36641615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia.
    Clarke MTM; Brinkmalm A; Foiani MS; Woollacott IOC; Heller C; Heslegrave A; Keshavan A; Fox NC; Schott JM; Warren JD; Blennow K; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2019 Dec; 11(1):105. PubMed ID: 31847891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of cerebrospinal fluid Neurogranin with Alzheimer's disease.
    Wang L;
    Aging Clin Exp Res; 2019 Feb; 31(2):185-191. PubMed ID: 29667155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
    Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.
    Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Shaw LM; Trojanowski JQ; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Ann Neurol; 2010 Mar; 67(3):308-16. PubMed ID: 20373342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele.
    Langbaum JB; Chen K; Caselli RJ; Lee W; Reschke C; Bandy D; Alexander GE; Burns CM; Kaszniak AW; Reeder SA; Corneveaux JJ; Allen AN; Pruzin J; Huentelman MJ; Fleisher AS; Reiman EM
    Arch Neurol; 2010 Apr; 67(4):462-8. PubMed ID: 20385913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
    Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
    J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
    Voevodskaya O; Sundgren PC; Strandberg O; Zetterberg H; Minthon L; Blennow K; Wahlund LO; Westman E; Hansson O;
    Neurology; 2016 May; 86(19):1754-61. PubMed ID: 27164711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer's Disease.
    Hohman TJ; Dumitrescu L; Oksol A; Wagener M; Gifford KA; Jefferson AL;
    PLoS One; 2017; 12(11):e0188501. PubMed ID: 29190651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease.
    Wang L; Gao T; Cai T; Li K; Zheng P; Liu J;
    Neurosci Lett; 2020 Jan; 715():134658. PubMed ID: 31794792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
    BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.
    Benitez BA; Karch CM; Cai Y; Jin SC; Cooper B; Carrell D; Bertelsen S; Chibnik L; Schneider JA; Bennett DA; ; ; Fagan AM; Holtzman D; Morris JC; Goate AM; Cruchaga C
    PLoS Genet; 2013; 9(8):e1003685. PubMed ID: 23990795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of plasma phosphor-tau181 with Aβ levels may vary by APOE ε4 status and sex among non-demented old adults.
    Cai Y; Fu P; Zhang X;
    Neurosci Lett; 2023 Apr; 802():137161. PubMed ID: 36858305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
    Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aβ amyloid, cognition, and APOE genotype in healthy older adults.
    Lim YY; Ellis KA; Ames D; Darby D; Harrington K; Martins RN; Masters CL; Rowe C; Savage G; Szoeke C; Villemagne VL; Maruff P;
    Alzheimers Dement; 2013 Sep; 9(5):538-45. PubMed ID: 23159043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease.
    Konijnenberg E; Tijms BM; Gobom J; Dobricic V; Bos I; Vos S; Tsolaki M; Verhey F; Popp J; Martinez-Lage P; Vandenberghe R; Lleó A; Frölich L; Lovestone S; Streffer J; Bertram L; Blennow K; Teunissen CE; Veerhuis R; Smit AB; Scheltens P; Zetterberg H; Visser PJ
    Alzheimers Res Ther; 2020 May; 12(1):65. PubMed ID: 32460813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.